Laboratory Corp. of America Holdings (LH) was Reiterated by Mizuho to “Neutral” according to the research note released today. The brokerage firm has raised the Price Target to $ 145 from a previous price target of $132 . Mizuho advised their investors in a research report released on Sep 15, 2016.
Many Wall Street Analysts have commented on Laboratory Corp. of America Holdings. Laboratory Corp. of America Holdings was Initiated by Citigroup to “Neutral” on Sep 9, 2016.
On the company’s financial health, Laboratory Corp. of America Holdings reported $2.31 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.30. The company had revenue of $2382.00 million for the quarter, compared to analysts expectations of $2334.01 million. The company’s revenue was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.09 EPS.
Laboratory Corp. of America Holdings closed down -0.35 points or -0.26% at $132.99 with 555,783 shares getting traded on Wednesday. Post opening the session at $133.73, the shares hit an intraday low of $132.58 and an intraday high of $133.87 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Aug 11, 2016, Lisa J Uthgenannt (Chief Human Resources Officer) sold 1,177 shares at $140.00 per share price. According to the SEC, on Aug 8, 2016, Glenn A Eisenberg (Chief Financial Officer, EVP) sold 8,000 shares at $140.38 per share price. On Aug 8, 2016, Robert E Jr Mittelstaedt (director) sold 992 shares at $140.15 per share price, according to the Form-4 filing with the securities and exchange commission.
Laboratory Corporation of America Holdings is an independent clinical laboratory company in the United States. Through a national network of laboratories the Company offers a range of clinical laboratory tests that are used by the medical profession in core testing patient diagnosis and in the monitoring and treatment of disease. The Company manages its operations through two segments: the Clinical diagnostics laboratory segment which includes core testing as well as genomic and esoteric testing; and the Other segment which consists of the Company’s non-United States clinical diagnostic laboratory operations in Ontario Canada. It also provides specialty testing services in the areas of allergy clinical trials diagnostic genetics women’s health cardiovascular disease identity forensics infectious disease endocrinology oncology coagulation occupational testing and pain management.